Calcium sensitisation impairs diastolic relaxation in post-ischaemic myocardium: implications for the use of Ca\(^{2+}\) sensitising inotropes after cardiac surgery

Yeong-Hoon Choi\(^a,b,*\), Douglas B. Cowan\(^c\), Thorsten C.W. Wahlers\(^a,b\), Roland Hetzer\(^d\), Pedro J. del Nido\(^c\), Christof Stamm\(^d\)

\(^a\)Heart Center of the University of Cologne, Department of Cardiothoracic Surgery, Cologne, Germany
\(^b\)Center of Molecular Medicine Cologne, Cologne, Germany
\(^c\)Children’s Hospital Boston and Harvard Medical School, Departments of Cardiac Surgery and Anesthesia, Boston, USA
\(^d\)Deutsches Herzzentrum Berlin, Department of Cardiothoracic Surgery, Berlin, Germany

Received 10 September 2008; received in revised form 30 April 2009; accepted 18 May 2009; Available online 17 July 2009

Abstract

Background: Calcium sensitising inotropes are increasingly being used in cardiac surgical patients. Theoretically, increasing contractile protein sensitivity to Ca\(^{2+}\) prevents the Ca\(^{2+}\) elevation associated arrhythmogenicity and potentiates the inotropic effect of catecholamines. On the other hand, we hypothesised that Ca\(^{2+}\) sensitisation exacerbates post-ischaemic myocardial stunning by impairing diastolic relaxation, which might have deleterious effects in postoperative cardiac surgical patients. Methods: In an isolated rabbit heart model, 45 min normothermic ischaemia with potassium-induced cardioplegic arrest was followed by 120 min reperfusion. Isovolumetric left ventricular (LV) function and myocardial oxygen consumption (MvO\(_2\)) were measured, and cytosolic Ca\(^{2+}\) was monitored by rhod-2 surface spectro-fluorometry. During reperfusion, ORG 30029 (250 µM) and levosimendan (0.5 µM) were used as Ca\(^{2+}\) sensitisers (ORG, \(n=6\), Levo, \(n=6\)), Ca\(^{2+}\)-desensitisation was induced with butanedione-monoxime (5 mM, BDM, \(n=6\)), and dopamine (20 nM) served as a representative catecholamine (\(n=6\)). To counteract the PDE III inhibiting properties of ORG and Levo, IGF-1 (0.1 µM) and parathyroid hormone (0.05 µM) were used. Results: As expected, ischaemia/reperfusion induced moderate cytosolic calcium overload. Dopamine increased LV contractility and MvO\(_2\) by augmenting the amplitude of the Ca\(^{2+}\) transient, but relaxation was unchanged despite increased contractile work. Conversely, ORG induced a rightward shift of the diastolic pressure-volume relationship in post-ischaemic hearts (diastolic pressure at 0.8 ml balloon volume 14.3 ± 5 mmHg, \(p=0.01\) vs control), but in non-ischaemic control hearts. With levosimendan, the Ca\(^{2+}\) sensitising effects were less pronounced (7.6 ± 3 mmHg, \(p=0.4\) vs control). By counteracting the PDE inhibiting effects of ORG and Levo using parathyroid hormone and IGF-1, the negative inotropic effects of Ca\(^{2+}\) sensitisation were unmasked. Conclusions: Calcium sensitisation improves systolic function and energetic efficiency. However, Ca\(^{2+}\) sensitisers should be used with caution during post-ischaemic reperfusion, as they may exacerbate myocardial stunning and thus impair cardiac output.

Keywords: Calcium sensitiser; Catecholamines; Ischaemia

1. Introduction

While pharmacologic treatment of post-operative pump failure remains largely based on catecholamines, novel types of inotropic agents have also found widespread clinical applications [1,2]. In principle, PDE III inhibitors increase contractility by targeting the same molecular end-effectors in cardiomyocytes via an increase of cyclic adenosine monophosphate (cAMP), but much of their clinical benefit is due to a potent afterload reduction. In the immediate postoperative situation, this can lead to a sustained loss of blood pressure that needs to be counteracted with vasoconstricting agents. Both, catecholamines and PDE III inhibitors have in common that they improve contractility by increasing the cytosolic Ca\(^{2+}\) concentration and the amplitude and slope of the calcium transient, using the physiological adrenergic downstream effectors that regulate
rapid changes in myocardial contractility. The net increase in intracellular calcium cycling, however, consumes additional energy resources, resulting in an increase of myocardial oxygen consumption that is disproportionate to that required by contractile work and may even activate cell-death-signalling cascades [3]. At least in theory, this effect is even more problematic when myocardial calcium cycling is already exacerbated, not only as in acute myocardial infarction but also as in surgical post-ischaemia settings. Another potential problem of post-ischaemic calcium over-load is the impairment of diastolic relaxation when cytosolic Ca$^{2+}$ is elevated, but adrenergic inotropes theoretically counteract this effect by protein kinase A-mediated reduction of contractile protein Ca$^{2+}$-sensitivity. In the 1990s, the concept of increasing contractile protein Ca$^{2+}$ sensitivity to improve contractility without affecting intracellular Ca$^{2+}$ cycling had been promoted, and some of those drugs have reached the clinical arena [4,5]. In patients with chronic heart failure, agents such as levosimendan are being used with increasing frequency, and several studies have evaluated Ca$^{2+}$ sensitisers in experimental models and in patients with post-surgical contractile failure. Since the role of Ca$^{2+}$ sensitisers in the clinical setting has not been clearly defined yet, we sought to test the hypothesis that Ca$^{2+}$ sensitisation can potentially impair diastolic relaxation and thus the global function of post-ischaemic hearts, when cytosolic Ca$^{2+}$ is already elevated. The rationale for doing so is that, theoretically, increased Ca$^{2+}$ affinity of the EF and Ca$^{2+}$ binding site on troponin C has a positive inotropic effect but, at the same time, impairs relaxation. In the clinical situation, this can impede not only diastolic filling of the heart but, via the Frank-Starling mechanism, also systolic function.

2. Methods

New Zealand white rabbits (2.5 kg) were anaesthetised by intravenous injection of ketamine (100 mg kg$^{-1}$) and heparin. The heart was rapidly excised, the aorta was cannulated and perfused in the Langendorf mode at 80 mmHg constant perfusion pressure with modified Krebs-Henseleit buffer, as previously described [3,6,7]. Temperature was maintained at 37°C and monitored with a probe placed in the right ventricle. The cava and pulmonary veins were closed and the pulmonary artery cannulated for collection of the venous effluent. A fluid-filled balloon connected to a Millar micromanometry catheter was placed in the left ventricle (LV) via the left atrium. The hearts were not paced. After 30 min stabilisation, the aorta was clamped and the hearts were subjected to 45 min global ischaemia at 35°C in a heated chamber filled with humidified room air with cardioplegic arrest induced by oxygenated, warm Krebs-Henseleit buffer, as previously described [3,6,7]. Temperatures were maintained at 37°C and monitored with a probe placed in the right ventricle. The cava and pulmonary veins were closed and the pulmonary artery cannulated for collection of the venous effluent. A fluid-filled balloon connected to a Millar micromanometry catheter was placed in the left ventricle (LV) via the left atrium. The hearts were not paced. After 30 min stabilisation, the aorta was clamped and the hearts were subjected to 45 min global ischaemia at 35°C in a heated chamber filled with humidified room air with cardioplegic arrest induced by oxygenated, warm Krebs-Henseleit buffer with 22.5 mM K⁺. Left ventricular pressure was measured pre-ischaemia and in 30 min intervals during reperfusion (Fig. 1). The LV balloon was filled stepwise in increments of 0.1 ml and diastolic and systolic pressure was recorded. No pre-filling of the balloon up to a pressure of 0 mmHg was performed; all balloon volumes given represent the actual filling. The data were used to plot the diastolic and systolic pressure-volume relationships. Between measurements, the balloon was deflated and the heart was beating unloaded. Coronary flow was measured by timed collection of the coronary effluent. Myocardial oxygen consumption (MO$_2$) was derived from the arteriovenous difference in O$_2$ tension (Stat Profile Plus 9, Nova Biochemical, Waltham, MA, USA), multiplied by coronary flow and divided by dry heart weight.

2.1. Cytosolic Ca$^{2+}$

Measurement of beat-to-beat intracellular calcium transients was performed in separate sets of intact perfused hearts, as we have previously described and validated in detail [3,6—9]. For quantitative measurement of cytosolic Ca$^{2+}$ at the end of the reperfusion period, the hearts were saturated with Ca$^{2+}$-sensitive dye rhod-2-AM (Molecular Probes, Eugene, OR, USA) after 100 min reperfusion by perfusion with the cell-permeable acetoxymethylster (rhod-2-AM; 0.5 mg/0.25 ml DMSO infused over 2 min at 37°C without re-circulation). Dye loading was followed by a 15-min washout period. A modified spectrophotometer (SLM-Aminco, Springfield, IL, USA) provided excitation light at 524 nm and recorded emission light at 589 nm. Tissue absorbance was quantified using the ratio of scattered excitation light at 524 nm (peak rhod-2 absorbance in myocardial tissue) and 589 nm. The change in absorbance over time was then used to account for differences in dye loading or changes in tissue dye concentration. At the end of each experiment 2,2'-dithiodipyridine (100 μM) was infused over a period of 2 min to induce calcium release from the sarcoplasmic reticulum. This was immediately followed by bolus injection of calcium ionophore A23187 (calceinimycin) in 10 ml 10% calcium solution to maximise calcium entry from the extracellular space and maximum fluorescence ($F_{max}$) was determined to calculate systolic and diastolic calcium concentration using the following equation:

$$[Ca^{2+}] = \frac{K_d \times F_t - F_0}{[A_t/A_{max}](F_{max} - F_0) - F_t - F_0]$$

where $[Ca^{2+}]$ is the free cytosolic calcium concentration, $K_d$ is the dissociation constant for rhod-2 with calcium at normothermia and pH 7.1, $F_t$ is fluorescence at a specific time point, $F_0$ is autofluorescence measured before dye loading, $A_t$...
and $A_{\text{max}}$ are tissue light absorbance at the specific time point or at the end of the experiment, respectively. In this model, rhod-2 has no measurable effect on cardiac function [7].

In a subset of hearts ($n = 3$ per group), a small amount of rhod-2-AM (0.1 mg in 0.1 ml DMSO) was administered just prior to the onset of the inotrope infusion. This allowed for qualitative registration of $\text{Ca}^{2+}$ transients for approximately 15 min.

### 2.2. Experimental groups

Control hearts ($n = 6$) were subjected to 45 min warm ischaemia with cardioplegic arrest followed by unmodified reperfusion for 120 min. Calcium sensitisation was induced by adding the calcium sensitising agent ORG 30029 (250 $\mu$M, $n = 6$) to the perfusate 5 min after start of reperfusion and given throughout the entire reperfusion period. To test a drug with calcium sensitising properties that is clinically available, levsimendan (0.5 $\mu$M) was used ($n = 6$). The concentrations we used in this study were determined in previous experiments and chosen so that a similar effect on LV contractility was induced. They are not comparable to the experiments and chosen so that a similar effect on LV contractility was induced. The same process was performed in order to compare energetic efficiency ($\text{RPP}/\text{MVO}_2$) and contractile calcium responsiveness ($\text{dp}/(\text{Ca}^{2+})$) data between dopamine and calcium-sensitiser treated hearts.

### 2.3. Animal care

All animals received humane care in compliance with the ‘Principles of Laboratory Animal Care’ formulated by the National Society for Medical Research and the ‘Guide for the Care and Use of Laboratory Animals’ prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1996). The protocol was reviewed and approved by the Internal Animal Care and Use Committee at Children’s Hospital Boston.

### 2.4. Statistical analysis

The sample size was chosen to be able to detect a difference in LV contractile function between dopamine-treated post-ischaemic hearts and post-ischaemic control hearts with a confidence level of 95% (normal distribution provided). The expected difference in mean value and confidence intervals were taken from previous experiments in similar models. Analysis of calcium recordings was performed using Sigma Plot software (version 4.0, SPSS Inc., Chicago, IL, USA). Data are expressed as the mean ± standard deviation and statistical analysis was performed using the SPSS software package (version 17.0, SPSS Inc., Chicago, IL, USA). All statistically relevant experimental data were normally distributed, and hence parametric tests were used. Data of unrelated experimental groups (intracellular $\text{Ca}^{2+}$, LV pressure at 0.8 ml balloon volume) were analysed by analysis of variance (ANOVA) followed by Dunnet’s post hoc test for multiple comparisons with a reference group. When the effects of different inotropes were compared, ‘control’ served as the reference group. In the experiments with IGF-1 or PTH, ‘Levo’ or ‘ORG’ were the respective reference groups. For comparison of the LV pressure-volume relationships under the influence of inotropes, the slope of each individual experiment was computed by linear regression (data series with $R^2 < 0.6$ were excluded), mean values and confidence intervals were calculated for each group, and the entire data set was analysed by ANOVA followed by Dunnet’s post hoc test for multiple comparisons with ‘control’ as the reference group. The same process was performed in order to compare energetic efficiency ($\text{RPP}/\text{MVO}_2$) and contractile calcium responsiveness ($\text{dp}/(\text{Ca}^{2+})$) data between dopamine and calcium-sensitiser treated hearts.

### 3. Results

#### 3.1. Inotrope effects in non-ischaemic hearts

As expected, dopamine as well as ORG and Levo exerted a positive inotropic effect, as evidenced by a leftward shift of the isovolumetric LV pressure-volume curve (Fig. 2A). Not surprisingly, contractile protein $\text{Ca}^{2+}$-sensitisation by Mg-ATPase inhibition with BDM was negative inotropic. Diastolic relaxation of the LV myocardium, indicated by the diastolic pressure-LV volume curve, was facilitated by BDM, but was not significantly affected by any of the inotropes (Fig. 2B). The data, thus, confirm the notion that, in non-ischaemic hearts, $\text{Ca}^{2+}$ sensitisers can improve contractility without impairing relaxation.

#### 3.2. Inotrope effects in post-ischaemic hearts

Isovolumetric contractility in post-ischaemic control hearts was moderately impaired as compared to non-ischaemic hearts, and maximum developed pressure at 0.8-ml balloon filling volume was 23% lower ($62 \pm 12$ mmHg vs $47 \pm 15$ mmHg, $p = 0.01$). Similar to the effects observed in non-ischaemic hearts, both $\text{Ca}^{2+}$ sensitisers induced a leftward shift of the systolic pressure-volume relationship (Fig. 3A), illustrating their potent positive inotropic effects even in hearts that had been subjected to ischaemia-reperfusion injury. Again, Mg-ATPase inhibition by BDM immediately reduced contractility. Diastolic relaxation in control hearts remained impaired after 120-min reperfusion (Fig. 3B), with a 86% higher minimum diastolic pressure at
0.8 ml than in non-ischaemic control hearts (4.9 ± 1.9 mmHg vs 9.1 ± 4.2 mmHg, \(p = 0.001\)). In hearts treated with Levo or dopamine, diastolic pressure tended to be lower than in control hearts (Fig. 3B), but the difference did not reach statistical significance (dopamine, 8.0 ± 2.5 mmHg \(p = 0.6\) vs control; Levo, 7.6 ± 2.8 mmHg, \(p = 0.4\) vs control). ORG, however, led to a clear leftward shift of the diastolic pressure-volume relationship (Fig. 3B). This impairment of relaxation is also demonstrated in Fig. 4 (14.3 ± 4.6 mmHg, \(p = 0.01\) vs control at 0.8 ml balloon filling volume).

### 3.3. Cytosolic calcium

The intensity change of the rhod-2 signal was first recorded during the onset of inotrope infusion during early reperfusion. Because \(F_{\text{max}}\) and \(A_{\text{max}}\) were recorded for calculation of the absolute cytosolic Ca\(^{2+}\) concentration nearly 120 min later, the early Ca\(^{2+}\) induced fluorescence can only be interpreted in qualitative fashion, that is, did Ca\(^{2+}\) rise or fall. The Ca\(^{2+}\) dependent rhod-2 signal clearly increased upon infusion on dopamine, while it remained largely unchanged with BDM and ORG. Infusion of Levo,
however, also resulted in an increase in signal intensity, implying that Levo also induces an acute rise in cytosolic Ca$^{2+}$, probably via its PDE III inhibiting properties (data not shown).

At the end of the reperfusion period, the cytosolic Ca$^{2+}$ concentration was quantitatively measured by rhod-2 spectrofluorometry in the intact isolated heart. As compared with non-ischaemic control hearts, Ca$^{2+}$ was significantly higher in post-ischaemic hearts (mean Ca$^{2+}$ = 0.84 ± 0.32 μM vs 0.52 ± 0.21 μM, p = 0.012). The behaviour of cytosolic Ca$^{2+}$ in response to inotropes is shown in Fig. 5. All positive inotropic drugs increased the mean cytosolic Ca$^{2+}$ concentration, but the increase was less pronounced in ORG treated hearts. When the data are expressed as the percent increase in Ca$^{2+}$, ORG induced a 47% ± 14% rise in Ca$^{2+}$, while Ca$^{2+}$ rose by 71% ± 21% or 82% ± 26% with Levo or dopamine, respectively.

### 3.4. Calcium sensitivity

When the LV developed pressure data at different balloon volumes are plotted as a function of the corresponding mean Ca$^{2+}$ concentration, we observed that ischaemia/reperfusion injury reduces contractile protein Ca$^{2+}$ sensitivity in control hearts (rightward shift of the devP/Ca$^{2+}$ relationship), and that dopamine or Levo stimulation leaves the Ca$^{2+}$ responsiveness largely unchanged. ORG treatment, however, induced a clear leftward shift of the devP/Ca$^{2+}$ relationship, indicating a Ca$^{2+}$ sensitising effect (Fig. 6A). A more direct and detailed measurement of contractile protein Ca$^{2+}$ sensitivity would require to work isolated myofibril preparations or with tetanised whole hearts, neither of which we could perform in the current series of experiments [8,9].

### 3.5. Metabolic efficiency

Myocardial work was expressed as the rate—pressure product (RPP) and was plotted as a function of myocardial oxygen consumption (MvO$_2$). When comparing contractile efficiency under the influence of dopamine and ORG (Fig. 6B), it is evident by the leftward shift of the RPP/MvO$_2$ relationship that ORG increases contractility in a metabolically more efficient manner. The RPP/MvO$_2$ relationship under the influence of Levo was not significantly different from that of dopamine (data not shown).

### 3.6. PDE activation

To distinguish between the direct calcium-sensitising effects of ORG and Levo and those induced by an increase in cAMP induced by PDE III inhibition, we sought to neutralise the inotrope-induced PDE III inhibition with IGF-1 or parathyroid hormone, both known to directly activate PDE III [10,11]. As seen in Fig. 7A, the already high diastolic pressure with ORG was not further elevated by IGF-1 or PTH,
PDE III-inhibiting effects seem to over-ride the negative clinically used drug. In the case of levosimendan, its potent Ca\(^{2+}\) sensitiser that has not been further developed into a clearly observable when ORG 30029 is used, a first-generation calcium cycling is already increased. These effects are impair diastolic function, especially when intracellular ing inotropes improve contractility in non-ischaemic and 4. Discussion III inhibition, indeed resulting in impaired relaxation in post-ischaemic hearts.

Second-generation Ca\(^{2+}\) sensitisers such as levosimendan or pimobendan have been more successful, primarily because it could reproducibly be demonstrated that they do not impair but perhaps even improve diastolic function in vivo [15–17]. This phenomenon is readily explained by the potent PDE III inhibiting effects of the recent Ca\(^{2+}\) sensitisers, prompting some to include them in the group of clinical ‘inodilators’. However, we could show that when the PDE III inhibition induced cAMP elevation and PKA activation is neutralised by PDE III agonists, the Ca\(^{2+}\) sensitising effects on relaxation (negative lusitropic) dominate. This is not to say that we would warn against the use of novel Ca\(^{2+}\) sensitisers, which have been shown to be effective even in postoperative cardiac surgical patients. However, diastolic function should always be monitored carefully, especially if more potent ‘true’ Ca\(^{2+}\) sensitisers will be available in the future. Moreover, simultaneous application of cAMP elevating drugs is perhaps advisable, since here the PKA induced depression of contractile protein Ca\(^{2+}\) sensitivity may be protective. In addition, current Ca\(^{2+}\) sensitisers also seem to have beneficial pre-conditioning effects on the myocardium that is chal-

![Graph](image-url)

**Fig. 7.** Minimum diastolic pressure at a balloon filling volume of 0.8 ml in post-ischaemic hearts treated with the calcium sensitisers ORG 30029 (ORG, A) or levosimendan (Levo, B). n = 5 per group to counteract their PDE III-inhibiting effect, parathyroid hormone (PTH) or insulin-like growth factor-1 (IGF-1) were given at the end of the reperfusion period. Thus, the impact of Ca\(^{2+}\) sensitisation on diastolic relaxation was unmasked. The p-values represent the results of ANOVA with Dunnet’s post hoc test for multiple comparisons (unpaired), with ‘Levo’ or ‘ORG’ as the respective reference group.

implying that PDE III inhibition does not play an important role here. In contrast, both IGF-1 and PTH induced a significant increase in diastolic pressure in Levo treated hearts (Fig. 7B: 7.6 ± 2.3 mmHg vs 16.1 ± 5.2 mmHg, p = 0.02 (PTH) and 15.4 ± 5.5 mmHg, p = 0.01 (IGF)). This phenomenon can be interpreted as an unmasking of the true Ca\(^{2+}\)-sensitising effects of Levo by a neutralisation of the PDE III inhibition, indeed resulting in impaired relaxation in post-ischaemic hearts.

4. Discussion

Our experiments confirmed the notion that Ca\(^{2+}\)-sensitis-ing inotropes improve contractility in non-ischaemic and post-ischaemic hearts. Ca\(^{2+}\) sensitisation alone, however, can impair diastolic function, especially when intracellular calcium cycling is already increased. These effects are clearly observable when ORG 30029 is used, a first-generation Ca\(^{2+}\) sensitisers that has not been further developed into a clinically used drug. In the case of levosimendan, its potent PDE III-inhibiting effects seem to over-ride the negative lusitropic actions of Ca\(^{2+}\) sensitisation, probably via the classic pathway of protein kinase A phosphorylation of contractile protein subunits. This mechanism is believed to preserve diastolic function in the presence of catecholamine induced cytosolic Ca\(^{2+}\) elevation. We hence believe that Ca\(^{2+}\) sensitisation should always be done with caution when Ca\(^{2+}\) overload of the myocardium is suspected.

It has long been established that high-dose or long-term therapeutic application of β1-stimulating catecholamines can have detrimental effects such as arrhythmogenicity, tachy-cardia, increased energy demand of the myocardium, induction of pro-apoptotic signalling cascades [3] or increased afterload via concomitant α-stimulation. Many of these problems are at least in part caused by the inevitable increase in cytosolic Ca\(^{2+}\), the main trigger of positive inotropy [12]. In principle, this also applies to specific PDE III inhibitors such as milrinone, but here the afterload-reducing effects have much more impact on the overall clinical performance (inodilators).

In theory, Ca\(^{2+}\) sensitisers that increase the affinity of troponin C or decrease that of troponin I for calcium and thereby elicit stronger contractile force for a given amount of Ca\(^{2+}\) offer an elegant solution [13]. Not only can the negative effects of elevated cytosolic Ca\(^{2+}\) be avoided, but myocardial work can become also more efficient in terms of energy metabolism, because less energy-rich phosphates are wasted on the removal of Ca\(^{2+}\) ions against immense concentration gradients. The saved energy can thus be used by the Mg-ATPase for the actual contractile work. At least, with respect to ORG 30029, we could clearly demonstrate this effect in our experiments, and other groups have found similar phenomena in different model, including large animals [14–18].

On the other hand, based on our current understanding of myocardial physiology, an artificial increase in contractile protein sensitivity to calcium that is not counteracted by PKA phosphorylation should impair diastolic relaxation of the myofilaments. When Ca\(^{2+}\) sensitisers were newly introduced in the 1990, this had been the subject of substantial controversy [19,20]. Partly because of these concerns, most of the first-generation Ca\(^{2+}\) sensitisers that were evaluated in the 1990s have not reached the clinical application phase. Second-generation Ca\(^{2+}\) sensitisers such as levosimendan or pimobendan have been more successful, primarily because it could reproducibly be demonstrated that they do not impair but perhaps even improve diastolic function in vivo [15–17]. This phenomenon is readily explained by the potent PDE III inhibiting effects of the recent Ca\(^{2+}\) sensitisers, prompting some to include them in the group of clinical ‘inodilators’. However, we could show that when the PDE III inhibition induced cAMP elevation and PKA activation is neutralised by PDE III agonists, the Ca\(^{2+}\) sensitising effects on relaxation (negative lusitropic) dominate. This is not to say that we would warn against the use of novel Ca\(^{2+}\) sensitisers, which have been shown to be effective even in postoperative cardiac surgical patients. However, diastolic function should always be monitored carefully, especially if more potent ‘true’ Ca\(^{2+}\) sensitisers will be available in the future. Moreover, simultaneous application of cAMP elevating drugs is perhaps advisable, since here the PKA induced depression of contractile protein Ca\(^{2+}\) sensitivity may be protective. In addition, current Ca\(^{2+}\) sensitisers also seem to have beneficial pre-conditioning effects on the myocardium that is chal-
lenged by ischaemia or oxidative stress [21,22], on which novel strategies for myocardial protection may be built.

4.1. Limitations of the study

The experimental model we used is highly artificial since crystalloid buffer perfused isolated hearts were used. We tried to design the ischaemia reperfusion protocol as close to the clinical setting during cardiac surgery as possible, including normothermic cardioplegic arrest. However, a more physiologic model was not possible because we wanted to monitor cytosolic calcium. This also implies that the inotrope concentrations we needed were empirically determined by monitoring the effect on LV function while increasing the infusion rate and are not comparable with those used in vivo and in patients, respectively. This may have important implications for the balance between Ca\textsuperscript{2+} sensitising and PDE III inhibiting actions, which are known to be highly dose dependent.

References


Appendix A. Conference discussion

Dr. D. Nordhaug (Trondheim, Norway): I have a few questions and a comment.

First: you warned that diastolic function may be impaired by calcium sensitisation. However, you have only presented pressure volume data, and I am wondering whether you had the opportunity in your instrumentation to look at other diastolic indices describing other phases of the diastole, for instance the derivative of the pressure decay, the time constant of relaxation, r, and so on? That is my first question.

My second question is: levosimendan is known to carry phosphodiesterase inhibiting effects, at higher doses at least, and it appears to act mainly as a calcium sensitiser at low doses. I am wondering what the rationale for your dosage that we used. Of course, one of the limitations of this model is that it is a highly artificial model since crystalloid buffer perfused isolated hearts were used. We tried to design the ischaemia reperfusion protocol as close to the clinical setting during cardiac surgery as possible, including normothermic cardioplegic arrest. However, a more physiologic model was not possible because we wanted to monitor cytosolic calcium. This also implies that the inotrope concentrations we needed were empirically determined by monitoring the effect on LV function while increasing the infusion rate and are not comparable with those used in vivo and in patients, respectively. This may have important implications for the balance between Ca\textsuperscript{2+} sensitising and PDE III inhibiting actions, which are known to be highly dose dependent.

Your other question was regarding?
and increasing the volume incrementally up to 1 ml. All diastolic pressure measurements have been carried out at 0.8 ml in all hearts which have been of similar size in order to have comparable results at the end.

We did not look into a calcium related calcium sensitisation of the myocyte. What we did, we measured calcium concentration during all phases by direct fluorescence spectroscopy of the whole heart using the rhod-2, and that was just referring to the calcium concentrations and the efficiency. And what we saw here was just the developed pressure over the intracellular calcium concentration, which showed a direct left shift in the hearts that had been treated with calcium sensitisers, in this case with ORG.

Dr G. Lutter (Kiel, Germany): I also have a question concerning the inhibiting effect of levosimendan on the myocardial phosphodiesterase. Can it be blocked differently, how is it done, and with which substances is it tested?

Dr Choi: The phosphodiesterase-inhibiting effect, which is like the same effect of e.g. milrinone, is just one of the features of levosimendan in this case. In order to counteract that effect, we treated the hearts with IGF-1 or parathyroid hormone.

I am sorry, then, I didn’t get the question properly.

Dr Choi: No, I thought you meant other substances that also block phosphodiesterase.

Dr Choi: No.